Reportable Segment Information (Tables)

12 Months Ended

Sep. 30, 2021

Segment Reporting [Abstract]

Segment Revenue, Operating Income (Loss) and Depreciation and Amortization

Segment revenue, operating income (loss), and depreciation and amortization were as follows:

	Fiscal Year
(In thousands)	2021			2020			2019
Revenue:
Medical Device	$	78,253		$	71,401		$	78,353
In Vitro Diagnostics		26,883			23,463			21,724
Total revenue	$	105,136		$	94,864		$	100,077
Operating income (loss):
Medical Device	$	4,683		$	(3,246	)	$	4,794
In Vitro Diagnostics		13,770			11,771			10,620
Total segment operating income		18,453			8,525			15,414
Corporate		(11,750	)		(9,776	)		(8,945	)
Total operating income (loss)	$	6,703		$	(1,251	)	$	6,469
Depreciation and amortization:
Medical Device	$	7,224		$	6,223		$	5,811
In Vitro Diagnostics		395			483			464
Corporate		398			557			1,037
Total depreciation and amortization	$	8,017		$	7,263		$	7,312

Geographic Revenue and Long-lived Assets

Revenue by geographic region was as follows:

	Fiscal Year
	2021			2020			2019
Domestic		79	%		78	%		81	%
Foreign		21	%		22	%		19	%

Long-lived assets by country, including property and equipment and intangible assets net of accumulated depreciation and amortization, respectively, were as follows:

	September 30,
(In thousands)	2021		2020
U.S.	$	25,920	$	25,273
Ireland		41,224		18,113